Collectively, our study emphasizes the value of integrating various dynamic eQTL (termiologies listed in Table 1) MR methods with differentially expressed gene analyses and clinical trial information in identifying novel immune‐related genes, minimizing pleiotropy, and prioritizing drug targets for cancers, such as EIF5A, ZNRD1, and PSMB5. This evidence concerns the gene POLR1H and cancer.